Stryker Co. (NYSE:SYK) Shares Sold by Mather Group LLC.

Mather Group LLC. reduced its stake in Stryker Co. (NYSE:SYK – Free Report) by 10.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,928 shares of the medical technology company’s stock after selling 709 shares during the period. Mather Group LLC holdings. in Stryker were worth $2,142,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also made changes to their positions in SYK. Stokes Capital Advisors LLC boosted its stake in Stryker by 1.4% in the third quarter. Stokes Capital Advisors LLC now owns 27,289 shares of the medical technology company’s stock worth $9,858,000 after acquiring an additional 389 shares during the last quarter. Miracle Mile Advisors LLC boosted its stake in Stryker by 569.2% in the third quarter. Miracle Mile Advisors LLC now owns 5,983 shares of the medical technology company’s stock valued at $2,161,000 after purchasing an additional 5,089 shares during the last quarter. Consilio Wealth Advisors LLC purchased a new position in Stryker in the third quarter valued at about $210,000. Diversified Trust Co grew its position in shares of Stryker by 5.8% during the 3rd quarter. Diversified Trust Co now owns 14,581 shares of the medical technology company’s stock worth $5,268,000 after buying an additional 800 shares in the last quarter. Finally, GAMMA Investing LLC lifted its position in Stryker by 38.7% in the third quarter. GAMMA Investing LLC now owns 2,901 shares of the medical technology company’s stock valued at $1,048,000 after acquiring an additional 810 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s shares.

Stryker trading up 1.6%

Shares of SYK stock opened at $350.81 on Wednesday. Stryker Co. has a 1 year low of $249.98 and a 1 year high of $374.63. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.68, and a quick ratio of 0.95. The company’s 50-day simple moving average is $350.01, and its 200-day simple moving average is $342.93. The firm has a market cap of $133.64 billion, a P/E ratio of 40.05, a PEG ratio of 2.71 and a beta of 0.91.

Stryker (NYSE:SYK – Get Your Free Report ) last announced its quarterly earnings data on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.79 by $0.02. The company had revenue of $5.42 billion during the quarter, compared to analysts’ expectations of $5.40 billion. Stryker had a net margin of 16.12% and a return on equity of 22.89%. The company’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same period in the previous year, the company earned $2.54 EPS. As a group, equities analysts estimate that Stryker Co. will show 12 EPS for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Stockholders of record on Monday, September 30th will be issued a $0.80 dividend. The ex-dividend date of this dividend is Monday, September 30. This represents a dividend of $3.20 on an annualized basis and a dividend yield of 0.91%. Stryker’s dividend payout ratio (DPR) is 36.53%.

Insider trading at Stryker

In other Stryker news, CFO Glenn S. Boehnlein sold 20,000 shares of Stryker stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $333.00, for a total transaction of $6,660,000.00. Following the transaction, the chief financial officer now directly owns 2,852 shares of the company’s stock, valued at $949,716. The transaction represented a decrease of 0.00 % in the stock holding. The sale was disclosed in a filing with the SEC, which is accessible via this hyperlink. In other news, CFO Glenn S. Boehnlein sold 20,000 shares of the business’s stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $333.00, for a total value of $6,660,000.00. Following the transaction, the chief financial officer now owns 2,852 shares of the company’s stock, valued at approximately $949,716. This trade represents a 0.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Viju Menon sold 600 shares of the business’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total transaction of $213,000.00. Following the sale, the insider now directly owns 9,069 shares of the company’s stock, valued at approximately $3,219,495. This trade represents a decrease of 0.00 % in the stock holding. The disclosure for this sale can be found here. In the last quarter, insiders sold 220,068 shares of company stock worth $71,811,372. 5.90% of shares are currently owned by company insiders.

Changes in Analyst Ratings

A number of brokerages have recently issued reports on SYK. Barclays boosted their target price on shares of Stryker from $374.00 to $402.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st. Morgan Stanley boosted their target price on Stryker from $345.00 to $350.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. UBS Group upped their price objective on shares of Stryker from $351.00 to $366.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Needham & Company LLC upped their target price on shares of Stryker from $392.00 to $393.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $386.00 target price on shares of Stryker in a research note on Wednesday, July 31st. Four equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Stryker currently has an average rating of “Moderate Buy” and an average price target of $379.37, according to MarketBeat .

Get the latest report on SYK

Stryker profile

(Free report)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopedics and Spine. The Orthopedics and Spine segment provides implants for use in total joint replacement, such as hip, knee and shoulder surgery, as well as trauma and extremity surgery.

Read more

Want to see what other hedge funds SYK owns? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Stryker Co. (NYSE:SYK – Free Report).

Get Stryker Daily news and reviews – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Stryker and related companies with MarketBeat.com’s FREE daily email newsletter.